[Effect of mestranol and chlormadinone acetate on basal and TRH-stimulated PRL secretion in Turner's syndrome].
In 19 patients aged from 12 to 24 years (average age 17.0 years) with Turner's syndrome the influence of mestranol and chlormadinone acetate on both basal and TRH stimulated PRL secretion was investigated by means of sequential stimulation test (0.5 g arginine hydrochloride/kg body weight, 25 micrograms GnRH and 200 micrograms TRH). This test was performed before, during the third until 5th cycle of treatment and 4 month after the end of therapy. PRL levels were determined by RIA. In most patients under treatment both basal and stimulated PRL showed an increase within the normal range. Hyperprolactinemic levels could be observed on one patient only.
K
K
Rudolf
S
S
Kunkel
L
L
Pelz
D000293:Adolescent; D000328:Adult; D001120:Arginine; D002648:Child; D002715:Chlormadinone Acetate / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D008656:Mestranol / Q000627:therapeutic use*; D010906:Pituitary Hormone-Releasing Hormones; D011388:Prolactin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone; D014424:Turner Syndrome / Q000097:blood / Q000188:drug therapy*
D010906:Pituitary Hormone-Releasing Hormones; D002715:Chlormadinone Acetate; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D001120:Arginine; D008656:Mestranol
Elinfluss von Mestranol und Chlormadinonazetat auf die basale und TRH-stimulierte PRL-Sekretion beim Turner-Syndrom.